First-in-Class GDF-8 Inhibitor Approved: A New Era for SMA and Muscle-Preserving Therapies

Recently, the FDA granted accelerated approval for Scholar Rock's Isembyld™ (Apitegromab) to be used in combination with Survival Motor Neuron 2 (SMN2) therapy for the treatment of patients with spinal muscular atrophy (SMA) aged 2 years and older. As the world's first SMA drug directly targeting muscle atrophy, Isembyld™ breaks the previous limitation of focusing solely on motor neuron protection by intervening in the disease process at the skeletal muscle level. Its approval is based on the pivotal Phase 3 SAPPHIRE trial: the results showed that the 10 mg/kg Isembyld™ group achieved a net improvement of 2.2 points in the HFMSE motor function score compared to the placebo group; 34.2% of the patients saw an HFMSE score improvement of around 3 points, compared to 13.5% in the placebo group. 

Image Source: Scholar Rock Official Website^[1]

The successful launch of Isembyld™ not only marks the entry of SMA treatment into a new era of combined "nerve + muscle" therapy but also, as the first commercialized drug validating this mechanism (with an estimated annual treatment cost of $310,000), thoroughly establishes the clinical feasibility of the GDF-8 target. This opens up imaginative possibilities for expansion into more fields, such as weight loss with muscle preservation. Spurred by this massive positive news, Scholar Rock's stock price surged over 23% in after-hours trading, bringing its current market value to over $6 billion. 

Maturation and Function of GDF-8

GDF-8 is a protein primarily expressed by skeletal muscle cells. Its full name is Growth Differentiation Factor 8, also known as Myostatin or MSTN, and it belongs to the transforming growth factor-β (TGF-β) superfamily. It mainly functions to limit skeletal muscle growth by negatively regulating it, maintaining muscle mass within a homeostatic range. Under various pathological conditions such as muscle atrophy, chronic diseases, and metabolic abnormalities, GDF-8 signaling may be abnormally regulated and associated with pathological processes like the decline in muscle mass. 

GDF-8 is synthesized as an inactive precursor and undergoes multi-step proteolytic processing to form the active ligand. First, the signal peptide is removed to form pro-GDF-8. Subsequently, Furin family proteases cleave at a conserved cleavage site between the propeptide and the C-terminal mature growth factor domain (GF domain), resulting in a non-covalently bound latent complex formed by the N-terminal prodomain and the C-terminal mature GF dimer (latent GDF-8). In this state, the prodomain wraps around and inhibits the receptor-binding ability of the GF dimer. Following this, BMP-1 or Tolloid family metalloproteinases further cleave the prodomain, causing it to dissociate from the GF dimer, thereby releasing the biologically active mature GDF-8. Mature GDF-8 exists as a disulfide-linked homodimer and initiates downstream signaling by binding to the Activin Type II receptor. 

GDF-8 protein structure and its activation process^[2]

The Activin Type II receptor (Activin RII, primarily ActRIIB) is the main cell surface receptor for GDF-8. When the mature GDF-8 dimer binds to ActRIIB with high affinity, it further recruits and activates the Type I receptor (ALK4 or ALK5), thereby triggering an intracellular cascade that inhibits synthesis and promotes degradation:

• Activating the canonical Smad2/3 pathway: The receptor complex induces the phosphorylation of Smad2/3, which binds to Smad4 and enters the nucleus, transcriptionally activating E3 ubiquitin ligases such as Atrogin-1 and MuRF-1, accelerating the degradation of muscle proteins.
• Suppressing the non-canonical Akt-mTOR pathway: It downregulates Akt activity, releasing its pro-synthetic effect on mTORC1 and inhibiting muscle protein synthesis; at the same time, it relieves the inhibition of Akt on FoxO, allowing FoxO to enter the nucleus and synergize with Smad to amplify the protein degradation signal. 
  

Through this dual regulation of blocking synthesis and driving degradation, the continuous activation of GDF-8 signaling ultimately leads to a reduction in skeletal muscle mass and muscle atrophy. 

GDF-8 Signaling Pathway^[3]

Drug Development Strategies for GDF-8

Targeting the Immature Precursor of GDF-8

Representative Drugs: Apitegromab, Emugrobart 

Isembyld™ (Apitegromab, also known as SRK-015) is a fully human IgG4λ monoclonal antibody that binds to a conformational epitope in the arm region of the GDF-8 prodomain. This region differs significantly from related proteins such as GDF-11 and Activin, thus enabling very high selectivity. Through a conformational effect, it stabilizes the Pro or Latent state, making it difficult for proteases like Tolloid to complete the subsequent activation; research shows that one IgG can bind to one GDF-8 homodimer. 

Mechanism of Action of Apitegromab^[4]

Schematic of Apitegromab Binding to Pro-GDF-8^[5]

Emugrobart (RO7204239, GYM329, RG6237) is a SMART-Ig developed by Roche utilizing recycling and sweeping antibody technology. Unlike Apitegromab, which prevents precursor activation, Emugrobart can continuously bind to and clear immature precursors from plasma and tissues, reducing the GDF-8 reservoir from the source, with a long half-life and low dosing frequency. Although its development in the neuromuscular disease field was terminated in March 2026 due to insufficiently robust improvements in motor function in SMA and FSHD (facioscapulohumeral muscular dystrophy) studies, because of its clear target degradation and good safety profile, Roche has fully pivoted to the obesity track to explore its potential in combination with GLP-1 for weight loss with muscle preservation. This may suggest that what determines efficacy is not the absolute reservoir of Latent GDF-8, but rather its dynamic conversion rate under pathological conditions and the clinical efficacy threshold that the reduction in Active GDF-8 must reach. 

Emugrobart binds to Latent GDF-8 in a pH-dependent manner^[6]

The greatest significance of targeting the immature precursor is that it answers the clinical challenge of "increasing muscle mass without increasing strength." The success of Apitegromab proves that sufficiently precise intervention nodes and appropriate intervention methods are capable of providing both safety and functional benefits. This strategy of precise conformational regulation at the source also provides highly valuable references for drug design targeting the entire TGF-β family and complex factor targets. 

Targeting the Mature Form of GDF-8

The representative drug is Regeneron's monoclonal antibody Trevogrumab (REGN-1033). Its mechanism involves directly freeing and neutralizing the already cleaved and mature GDF-8 homodimers in circulation via a monoclonal antibody, preventing them from binding to downstream cell membrane receptors. 

On September 17, 2025, Regeneron announced the results of the Phase 2 COURAGE clinical trial of Trevogrumab in combination with Semaglutide. The trial confirmed that in weight loss achieved with Semaglutide monotherapy, approximately 33% of the weight loss came from muscle loss. The combination with Trevogrumab successfully reduced muscle loss by approximately 42%~49%, while simultaneously increasing the reduction in fat to 17.3%~19.1% (higher than the 15.7% with monotherapy). This achieved the high-quality fat loss goal of cutting muscle loss in half while directing the weight loss more towards pure fat, with improvements also seen in metabolic indicators such as waist circumference and blood lipids. 

Phase 2 clinical COURAGE trial data for Trevogrumab combined with Semaglutide^[7]

Another noteworthy route is Biohaven's Taldefgrobep alfa (BMS-986089, BHV-2000). It utilizes a unique non-antibody Adnectin-Fc fusion protein design, with a molecular weight significantly lower than traditional IgG monoclonal antibodies, resulting in higher transdermal penetration and target inhibition efficiency in muscle tissues. It possesses two inhibitory mechanisms: on one hand, it specifically neutralizes Mature GDF-8; on the other hand, the resulting GDF-8-drug complex can further competitively block the ActRIIB receptor signaling pathway. Currently, the drug has completed data collection in its Phase 3 clinical trial for SMA and has expanded into the obesity and weight loss with muscle preservation track. 

Taldefgrobep improves body composition in non-obese adults and has the potential for monthly administration in obese patients^[7]

The advantage of strategies targeting mature GDF-8 lies in their extremely high targeting specificity, without interfering with unactivated precursors. The challenges are that the mature form has a short half-life and strong receptor affinity, requiring higher drug concentrations for effective clearance, and it easily induces a compensatory response of accelerated precursor cleavage. In the future, utilizing their high specificity and low toxicity/side effects to pivot towards safe, multi-target bispecific antibodies (e.g., GDF-8 x Activin A) for synergistic weight loss and muscle preservation will be the core development trend for this type of strategy. 

Ligand Traps

The representative drug is Keros's KER-065 (Rinvatercept). KER-065 is a modified ActRII-Fc trap protein (Ligand Trap) that has undergone recombinant structural modification via protein engineering, and is currently in Phase 2 clinical development for Duchenne muscular dystrophy and obesity. This molecule features specific site mutations at the binding interface, maintaining high-affinity binding to GDF-8 and Activin A/B, while simultaneously reducing its binding affinity for BMP-9 and BMP-10 by more than 100-fold. This modification eliminates, at the source, the vascular toxicities such as epistaxis and telangiectasia caused by the disruption of vascular endothelial homeostasis seen with first-generation trap proteins (e.g., ACE-031). Phase 1 clinical data from healthy subjects showed that KER-065 was safe and well-tolerated. It not only verified a favorable vascular safety profile but also demonstrated a body composition improvement effect by increasing muscle mass and bone density while simultaneously decreasing body fat mass. 

Administration of KER-065 can achieve bidirectional improvements: increasing muscle mass and decreasing body fat mass^[9]

Summary: Different strategies correspond to different pathological scenarios. Immature precursor blockers, with their high selectivity and extremely low toxicity, occupy the core position in rare neuromuscular diseases and precise monotherapy. Mature state neutralizing antibodies, relying on their good safety profiles, have become indispensable combinatorial tools in multi-target combination therapies. Meanwhile, ligand traps, by simultaneously capturing ligands like GDF-8 and Activin, demonstrate significant metabolic regulatory capabilities (balancing both muscle building and fat loss) and have found a fitting stage in the massive GLP-1 market for weight loss with muscle preservation. 

KACTUS GDF-8 Protein Tools for Myopathy and Weight Loss with Muscle Preservation

Addressing the drug development needs in the fields of muscular dystrophy, neuromuscular diseases, and weight loss with muscle preservation, KACTUS has created exclusive and featured Pro-GDF-8 proteins and deeply laid out a high-quality protein matrix covering full conformational forms (including Latent and Mature) as well as downstream receptors. This series of products covers multiple species and diverse tags, and has undergone rigorous quality inspection and activity validation. They highly match the R&D process requirements, such as antibody screening and binding affinity determination, providing strong support for precursor intervention and multi-target synergistic drug development.

Data Examples

Immobilized Human pro GDF-8, His Tag at 1 μg/ml (100 μl/well) on the plate. Dose response curve for Apitegromab, hFc Tag with the EC50 of 23.4 ng/ml determined by ELISA (QC Test).

Loaded Apitegromab, hFc Tag on ProA-Biosensor can bind Human pro GDF-8, His Tag with an affinity constant of 25.10 nM as determined in BLI assay (QC Test).

Immobilized Human Latent GDF-8, His Tag at 1 μg/ml (100 μl/well) on the plate. Dose response curve for Apitegromab, hFc Tag with the EC50 of 23.1 ng/ml determined by ELISA (QC Test).

Loaded Apitegromab, hFc Tag on ProA-Biosensor can bind Human Latent GDF-8, His Tag with an affinity constant of 18.50 nM as determined in BLI assay (QC Test).

Determined by its ability to inhibit the proliferation of MPC-11 cells. The expected ED50 for this effect is <30 ng/ml (QC Test).

Product List

References

[1] https://scholarrock.com/
[2] Circulating Growth Differentiation Factor 11/8 Levels Decline With Age. Circ Res. 2016 Jan 8;118(1):29-37. doi: 10.1161/CIRCRESAHA.115.307521.
[3] Garber K. No longer going to waste. Nat Biotechnol. 2016 May 6;34(5):458-61. doi: 10.1038/nbt.3557.
[4] https://scholarrock.com/wp-content/uploads/2025/10/Tirucherai-WMS-2025.pdf#toolbar=0
[5] Structural basis of specific inhibition of extracellular activation of pro- or latent myostatin by the monoclonal antibody SRK-015. doi: 10.1074/jbc.RA119.012293.
[6] Novel myostatin-specific antibody enhances muscle strength in muscle disease models. doi: 10.1038/s41598-021-81669-8.
[7] https://investor.regeneron.com/node/31266/pdf
[8] Biohaven's 2025 Investor Presentation.
[9] ir.kerostx.com